stockrow
Saturday 7 November 2026
Export INMB’s income statement to Excel — free account
INmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
- Revenue
- +8.70%
- EPS
- +95.2%
- Free cash flow
- +55.4%
Quarter to June 2026, against a year earlier
1.12
0.06
−5.08%
Follow INMB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (74.82%) | (168.78%) | (165.16%) | (155.77%) |
+8 more TTM periods Free account |
|
| (57.08%) | (130.78%) | (127.75%) | (115.83%) | ||
ROIC |
(646.94%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(96.06%) | (226.87%) | (204.82%) | (206.22%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.61) | (0.72) | (0.95) | (1.19) | |
Free Cash Flow |
(16.43) | (19.16) | (23.62) | (31.55) | |
Capital Expenditures |
(1.47) | — | (1.04) | (0.90) | |
| Other line items | |||||
Cash ROIC |
(42.38%) | (46.75%) | (48.94%) | (59.40%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.81 | 0.46 | 0.49 | 0.61 | |
Depreciation/Fixed assets |
0.16 | 0.16 | 0.11 | 0.08 | |
Capex/Depreciation |
(7.29) | 0.00 | (9.92) | (12.32) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (0.72) | (0.91) | (1.15) | |
Capex per Share |
(0.06) | 0.00 | (0.04) | (0.03) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates